阿帕蒂尼
医学
阿法替尼
酪氨酸激酶
肿瘤科
内科学
突变
蛋白激酶结构域
肺腺癌
腺癌
肺癌
ErbB公司
吉非替尼
癌症
癌症研究
酪氨酸激酶抑制剂
表皮生长因子受体
生物
受体
遗传学
突变体
基因
作者
Chao Sun,Yinghui Xu,Xu Wang,Ye Guo,Shi Qiu,Guoguang Shao,Zhiguang Yang,Yunpeng Liu,Peng Zhang,Kewei Ma
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2021-02-09
卷期号:32 (4): 469-473
被引量:4
标识
DOI:10.1097/cad.0000000000000995
摘要
Lung cancer is one of the most important and lethal cancers in the world. Human epidermal growth factor 2 (HER2) is a member of the erbB receptor tyrosine kinase family. The incidence of HER2 kinase domain mutations in adenocarcinoma of lung ranges from 1% to 3%. HER2 V659D mutation is located in the trans-membrane domain (TMD) with only a few cases reported before, and importantly, there were no more standard and effective ways for this kind of diseases until now. Afatinib irreversibly blocks all kinase-competent HER family members. Apatinib is one of the small-molecule oral anti-angiogenesis-targeted agents developed firstly in China, and it’s a highly selective inhibition of the activity of VEGFR-2. This report presents an advanced lung adenocarcinoma patient with HER2 V659D mutation who was treated with combination of Afatinib and Apatinib. He achieved good efficacy and tolerable adverse reactions.
科研通智能强力驱动
Strongly Powered by AbleSci AI